Dr Reddys Laboratories (RDY) Long-Term Deferred Tax (2018 - 2026)

Dr Reddys Laboratories (RDY) has reported Long-Term Deferred Tax for 9 consecutive years, with $239.0 million the latest figure, recorded in Q1 2026.

• Quarterly Long-Term Deferred Tax rose 10.14% year-over-year to $239.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $239.0 million (up 10.14% YoY) and the FY2026 annual result came in at $239.0 million, up 10.14% from the prior year.
• Long-Term Deferred Tax rose to $239.0 million in Q1 2026 per RDY's latest filing, from $217.0 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for RDY reached as high as $239.0 million in Q1 2026 and fell as low as $88.0 million in Q1 2023.
• A 5-year average of $156.2 million and a median of $129.0 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax slipped 25.52% — and 2025, when it jumped 68.22%.
• Year by year, Long-Term Deferred Tax stood at $108.0 million in 2022, then fell by 18.52% to $88.0 million in 2023, then soared by 46.59% to $129.0 million in 2024, then jumped by 68.22% to $217.0 million in 2025, then grew by 10.14% to $239.0 million in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $239.0 million, $217.0 million, and $129.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.